Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

14.45 -0.22 (-1.50%)
Streaming Delayed Price Updated: 1:29 PM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
Earnings Outlook For Omeros ↗
Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years ↗
Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA... 
Via Benzinga
News headline image
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
From Omeros Corporation
Via Business Wire
News headline image
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
From Omeros Corporation
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
News headline image
3 Beaten-Down Biotech Stocks -- Can They Recover? ↗
Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year. 
Via The Motley Fool
News headline image
NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation ↗
San Diego, CA -- (SBWIRE) -- 10/22/2021 -- An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements. 
Via SBWire
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Goldman Sachs boosted Walmart Inc. (NYSE:WMT) price... 
Via Benzinga
News headline image
46 Biggest Movers From Yesterday ↗
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
News headline image
Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA ↗
The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Benchmarks Pare Losses on Upbeat Earnings Outlook ↗
The major benchmarks are paring earlier losses at midday, fresh off of their best week in months as earnings season kicks off. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of... 
Via Benzinga
News headline image
Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet ↗
Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Here's Why Omeros Is Sinking Further Today ↗
Bad news the company received today from the FDA surprised investors more than it probably should have. 
Via The Motley Fool
News headline image
34 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates ↗
Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion.... 
Via Benzinga
News headline image
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
35 Biggest Movers From Friday ↗
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
News headline image
28 Stocks Moving In Friday's Mid-Day Session ↗
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 ↗
Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ: 
Via Benzinga
News headline image
OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.